Corrected: BUZZ-First Tracks surges on positive results from celiac disease drug trial (October 12)

First Tracks Biotherapeutics

12/10/2026 12:52

Corrects last bullet in October 12 buzz to say company was spun out of AnaptysBio in April and did not do an IPO
** Shares of biotechnology company First Tracks Biotherapeutics TRAX.O soar 16.2% to $37 premarket
** Co announces positive top-line results for its drug, ANB033, in gluten-challenge study in celiac disease
** ANB033 is co's experimental antibody drug to treat autoimmune and inflammatory diseases, including celiac disease 
** Celiac disease is an autoimmune condition in which eating gluten damages the small intestine 
** TRAX says ANB033 limits symptoms worsening during 14 days of gluten consumption
** Reports ANB033 was well tolerated, with no serious adverse events
** Expects top-line data from Cohort 2 of its ANB033 celiac disease trial in Q1 2027 and eosinophilic esophagitis trial in Q3 2027
** Expects to start Phase 2 development of ANB033 in vitiligo and another indication in H1 2027
** TRAX shares have nearly doubled since their Nasdaq debut in April after being spun out of AnaptysBio ANAB.O

 (Reporting by Jayasree Prabhu)
 ((jayasree.prabhu@thomsonreuters.com))